[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@RNAiAnalyst Avatar @RNAiAnalyst Dirk Haussecker

Sarepta Therapeutics ($SRPT) has received positive news regarding its gene therapy, Elevidys, as the FDA has lifted a hold on the treatment. The company's subcutaneous delivery of a Huntington's disease candidate has shown impressive results, although it does not target exon X. Additionally, Sarepta's partnership with Arrowhead Pharmaceuticals ($ARWR) may be renegotiated following the recent news.

Engagements: XXXXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXXX #

Followers Line Chart

CreatorRank: XXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence stocks XXXX% finance XXXX% cryptocurrencies XXX% countries XXXX%

Social topic influence $srpt #7, $ntla #5, $qure #9, $alny #9, $srrk #3, $ions #5, $pepg #5, $regn #8, the only 0.74%, $wve #2

Top accounts mentioned or mentioned by @geneinvesting @grok @bambossie81 @hall8jack @djtblows69 @hannibalspeaks @drmakaryfda @jamesmclaw70633 @adamfeuerstein @towiu2 @jfais20 @hulksmash8181 @biopharmiq @auditor112017 @pearlf @alamentarius @zhaoweiasu @martinshkreli @nociftw @jmaraganore

Top assets mentioned Sarepta Therapeutics, Inc. (SRPT) Intellia Therapeutics, Inc (NTLA) uniQure N.V. (QURE) Alnylam Pharmaceuticals, Inc. (ALNY) Scholar Rock Holding Corporation Common Stock (SRRK) Ionis Pharmaceuticals, Inc. Common Stock (IONS) Regeneron Pharmaceuticals Inc (REGN) Biogen Inc (BIIB) Akropolis (AKRO) Avidity Biosciences, Inc. Common Stock (RNA) Dyne Therapeutics, Inc. Common Stock (DYN) Arrowhead Research Corporation (ARWR) Smart Layer Network (SLN) MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Merck & Co., Inc. (MRK) Novavax Inc (NVAX) Moderna Inc (MRNA) Novo-Nordisk (NVO) Sanofi (SNY) Synthetify (SNY) PTC Therapeutics, Inc. (PTCT)

Top Social Posts #

Top posts by engagements in the last XX hours

"$ntla $srpt cant see Adam's tweets but is he squealing yet Do his handlers need to up the retainer"
X Link @RNAiAnalyst 2025-10-08T17:01Z 20.5K followers, 8438 engagements

"$ovid m2c: new data not THAT exciting. A step forward. Instead would argue stock action more reflective of current stage of biotech revival giving companies w/ earlier-stage assets but with credible expertise (be it platform or disease-specific here epilepsy) new lease on life"
X Link @RNAiAnalyst 2025-10-05T08:44Z 20.5K followers, 3238 engagements

"$MGX tomorrow is $IONS R&D day. Maybe they will grace them with a mention. Must be the only pure-play #CRISPR stock trading at XX% discount. Today Algen-AstraZeneca CRISPR functional genomics deal involving AI. Metagenomi maybe hottest CRISPR-AI stock out there"
X Link @RNAiAnalyst 2025-10-06T15:25Z 20.5K followers, 3026 engagements

"$qure $pepg today we are seeing groundbreaking data for X of the most common severe monogenic diseases: Huntington's and myotonic dystrophy type X. A XXXX% splicing correction hints at a cure for muscle-related issues in DM1; for Huntington's exon 1-knockdown will ultimately be complemented by strategies to slow down triplett expansion"
X Link @RNAiAnalyst 2025-09-24T21:26Z 20.5K followers, 11.2K engagements

"$alny doses 1st patient in 11k subject CVOT of biannual anti-hypertensive #angiotensinogen RNAi. Triggers $300M milestone from partner Roche"
X Link @RNAiAnalyst 2025-10-01T11:48Z 20.5K followers, 3243 engagements

"$NTLA I believe the ATTR-PN phase X data will be even better than the one reported today mainly because p3 does not include patients that had progressed on $ALNY's RNAi agents before. As you can see they did worse than knockdown-naive subjects"
X Link @RNAiAnalyst 2025-09-25T19:12Z 20.5K followers, 4220 engagements

"$ALNY presents potentially game-changing argument for why ATTR-CM patients should take a silencer and not a stabilizer. -- vutrisiran reduces gastrointestinal events REGARDLESS of 1) tafamidis (which does not reduce baseline gastro effects) and 2) mutant or wild-type ATTR-CM. This is a reminder that ATTR is a multi-system disease and stabilizers possibly only good for cardiomyopathy manifestations. Important readthrough to $BBIO and $NTLA"
X Link @RNAiAnalyst 2025-09-29T17:53Z 20.5K followers, 10.4K engagements

"Most important slide. Note how soon bilirubin moves.quite different from non-fatal ALIs. Question for AAV aficionados: is there similar pattern in past cases of systemic AAV ALFs $srpt"
X Link @RNAiAnalyst 2025-10-11T14:49Z 20.5K followers, 10.7K engagements

"@Nizz1212 good news to have more clarity on cases; solid recs too. $srpt"
X Link @RNAiAnalyst 2025-10-11T11:59Z 20.5K followers, XXX engagements

"More success for locally delivered #AAV gene therapy. $qure $regn $alsen.pa $bntc"
X Link @RNAiAnalyst 2025-10-12T18:21Z 20.5K followers, 9683 engagements

"#biotech I also notice how giddy I have become and tempted to ride some of the momentum names outside my normal lanes. Bad idea Dirk. Stay focused on DM1 $ntla ATTR-CM readout in Nov and $wve inhibin E data"
X Link @RNAiAnalyst 2025-10-08T09:40Z 20.5K followers, 3136 engagements

"$SRRK 'if I do wanna be on treatment I NOW HAVE THAT OPTION'. I doubt she is referring to the $BIIB drug"
X Link @RNAiAnalyst 2025-09-22T20:25Z 20.5K followers, 5207 engagements

"$srpt convened an expert panel on enhancing safety of Elevdiys. Observations: in both cases of ALF liver enzymes first increased X weeks post dose death 11weeks post dose (predictable time-course). #bilirubin was not increased in both fatalities shortly after liver enzyme increases vs no such observations in the XX non-fatal ALIs No relationship with weight/dose but likely liver health (steatosis) and consumptive coagulopathy may ultimately cause of T cell-initiated fatal course. Recs: more sensitive monitoring of liver tox markers; TREAT at earliest sign of liver enzyme increase with"
X Link @RNAiAnalyst 2025-10-11T11:26Z 20.5K followers, 16.7K engagements

"$60B MC $alny's biz dev team needs to be summarily fired for not taking advantage of #CRISPR firesale prices not long ago. CRISPR $ntla will eat a lot of its market share in the not too distant future. What were they thinking"
X Link @RNAiAnalyst 2025-10-08T18:14Z 20.5K followers, 4811 engagements

"$ntla this Biocryst acquisition of $atxs made my day. First claimimf that patients CLEARLY prefer oral for prophylaxis now saying 'sorry we lied to you: every X months and less often much better'. Clearly freaking out about the coming one-time cure. $bcrx"
X Link @RNAiAnalyst 2025-10-14T14:19Z 20.5K followers, 5754 engagements

"@JoseRestonVA What about the CVR Basically for free just have to tie up capital for a bit. Or are you concerned abt antitrust Could there also be a higher offer from $mrk $akro"
X Link @RNAiAnalyst 2025-10-11T12:43Z 20.5K followers, XXX engagements

"Anybody knows whether 'Dear Leader' got an mRNA or the $nvax protein covid vax $bntx $mrna"
X Link @RNAiAnalyst 2025-10-11T11:06Z 20.5K followers, 5547 engagements

"$NTLA unlike vutrisiran mNIS+7 improves in majority of ATTR-PN patients after NTLA-2001 one time treatment. Another @NEJM publication in the bag. $alny"
X Link @RNAiAnalyst 2025-09-25T14:25Z 20.5K followers, 3791 engagements

"$ntla believe the next major re-rating of stock occurs when commercial uptake shows patients/KOLs love that type of medicine"
X Link @RNAiAnalyst 2025-10-14T20:34Z 20.5K followers, 3633 engagements

"$pepg stock is held almost exclusively by tutes e.g. RA Capital (32%) Point72 (8%); I seem to be the only tax-paying non-tute 😜. Regardless considering $RNA and $DYN market caps of $6B and $2B respectively would be unfair to see offering at anything less than $300M pre-money. $pepg should have announced data first then do an offering after full trading day. Maybe RA Capital wants to add more and that's why"
X Link @RNAiAnalyst 2025-09-24T21:22Z 20.5K followers, 6332 engagements

"$WVE AATD was never the big money maker for Co. It validated the #RNAediting platform. For most applications XX% editing is plenty. Yet it sold off on $BEAM/repeat admin data when obesity and cardiovascular are the crown jewels. Forget about Huntington's and DMD"
X Link @RNAiAnalyst 2025-10-09T20:53Z 20.5K followers, 3524 engagements

"$qure IMO the coming intrathecal RNAi competition need to show superiority to one-time AMT-130. Life-long progressive disease. $alny $arwr"
X Link @RNAiAnalyst 2025-09-26T08:01Z 20.5K followers, 4051 engagements

"💪week: $RNA (also M&A rumors) $DYN (pin action+WMS) $PEPG $SRPT (WMS25). $qure AMT-130 data presentation"
X Link @RNAiAnalyst 2025-10-05T08:41Z 20.5K followers, 4499 engagements

"$qure wouldnt it be easy for regulators to check the validity of the analysis by randomly picking XX patients meeting trial entry criteria from one of the Nat Hx databases and then propensity match them and run the simulation Interestingly no peep yet from Vinay nor Marty. Maybe still aligning their messaging"
X Link @RNAiAnalyst 2025-10-09T18:36Z 20.5K followers, 4098 engagements

"$ALNY $REGN: The POWER of #genetic medicine illustrated: (complement C5) mono RNAi better than RNAi-mAb combo despite XX% vs XX% complement assay inhibition respectively for myasthenia gravis. -- why I also expect $NTLA's ATTR and HAE treatment to kick ass. $SLN"
X Link @RNAiAnalyst 2025-08-26T13:28Z 20.5K followers, 6080 engagements

"A backup site What a revolutionary idea. $regn $srrk"
X Link @RNAiAnalyst 2025-10-08T09:38Z 20.5K followers, 4001 engagements

"@minimus0987 @SuperDuperDrugs @sonichedgefund @grok CEO said X weeks ago that FDA already saw and reviewed the 240mg dose expansion data incl safety and knockdown and greenlighted 400mg. $wve"
X Link @RNAiAnalyst 2025-10-10T14:23Z 20.5K followers, XXX engagements

"$srrk $regn smart resourceful traders probably have a list with upcoming PDUFAs for new formulations that rely on the Catalent site. Can I see this list Catalent insiders probably shorting all of them now"
X Link @RNAiAnalyst 2025-10-13T16:55Z 20.5K followers, 6351 engagements

"@_financeken @Vulpescap Beautiful dose response. For measuring splice correction n=6 is adequate. $pepg"
X Link @RNAiAnalyst 2025-09-24T21:32Z 20.5K followers, XXX engagements

"$BIIB $IONS CRL issued for another SMA drug today high-dose nusinersen; and once again it is because of CMC"
X Link @RNAiAnalyst 2025-09-23T20:47Z 20.5K followers, 5572 engagements

"$prqr I will jinx it but the only explanation for not hearing anything from the company would be M&A. Anything else would be reason for panic. Will have to see whether $nvo jas some leftovers in poxkets after today's $akro acquisition"
X Link @RNAiAnalyst 2025-10-09T19:49Z 20.5K followers, 3631 engagements

"@Zappitelli1 No way. I'd be terrified having a significant long position going into earnings. Sandy has strung along shareholders quarter after quarter.and he'll continue to do so likely with another highly dilutive financing. $sgmo"
X Link @RNAiAnalyst 2025-08-05T17:59Z 20.5K followers, 1203 engagements

"@anna51296106 $srpt is now studying sirolimus in non-ambulatory. My guess is that if safety positive then back on label h2 2026. $srpt"
X Link @RNAiAnalyst 2025-10-11T12:22Z 20.5K followers, 1551 engagements

"@17thfellow Actually leaving XX% on the table is a bad idea regardless of whether I did 'double down' or not following the crash or whether it was $mltx or any other stock"
X Link @RNAiAnalyst 2025-10-11T04:44Z 20.5K followers, XXX engagements

"$SLN may be the first RNAi casualty due to competition from China. This Co has done X over last decade in terms of progressing their tech incl extrahepatic delivery as more+more partnering competition for Lpa complement etc emerges"
X Link @RNAiAnalyst 2025-08-29T14:34Z 20.5K followers, 2367 engagements

"$SNY's anti-TNFalpha-OX40 dual-targeting nanobody rocks in hidradenitis supp with unprecedented p2 HiSCR75 delta of XX% (cf $MLTX's dual targeting-nanobody 29%)"
X Link @RNAiAnalyst 2025-09-17T07:43Z 20.5K followers, 11.2K engagements

"$srpt no sirolimus PROPHYLAXIS X of XX with acute liver injury. Sirolimus prophylaxis: zero of X. Proph well tolerated. Single center experience"
X Link @RNAiAnalyst 2025-10-08T12:01Z 20.5K followers, 12.3K engagements

"This guy nailed it. FILL-FINISH.I remember @JMaraganore X decades ago stressing that work not done until fill-finish secured. The irony is that Askshay Vaishnaw went from $ALNY to $SRRK"
X Link @RNAiAnalyst 2025-10-13T13:47Z 20.5K followers, 6194 engagements

"$srpt getting more and more bullish ahead of earnings: 1) no more deaths since ambulatory only 2) sirolimus as backup (will have to see whether prophylaxis or on-demand wins out) 3) current market would support a $srpt pipeline even without Elevidys"
X Link @RNAiAnalyst 2025-10-08T18:21Z 20.5K followers, 11.6K engagements

"$qure after the initial euphoria and acknowledging the credibility of KOL Tabrizi and Wild can sense a heated bull-bear battle bubbling up. Think $srpt Elevidys. There are vested interests that dont like AMT-130. I also predict that Adam F will become their spokesperson"
X Link @RNAiAnalyst 2025-10-11T22:36Z 20.5K followers, 6562 engagements

"Small #CRISPR platform Co (see also $MGX) Mammoth Biosciences showcases ApoC3 disruption data in NHPs. XX% ApoC3 lowering. Wants to enter clinic for FCS in 2026 to compete with $IONS $ARWR. Looks like nuclease-based. I would recommend base or prime also for gene inhibition"
X Link @RNAiAnalyst 2025-10-09T20:50Z 20.5K followers, 3266 engagements

"@Anonym64382296 @JMaraganore Not on the yahoo feed nor an SEC filing. Had to find this on their website: $SRRK"
X Link @RNAiAnalyst 2025-10-13T14:02Z 20.5K followers, XXX engagements

"#SMA there is no apparent disadvantage from treating CNS only after intrathecal ASO (nusinersen) admin vs systemic small molecule (risdiplam). Very comprehensive analysis. $ions $biib $ptct"
X Link @RNAiAnalyst 2025-10-08T10:28Z 20.5K followers, 2637 engagements